{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T06:36:45Z","timestamp":1782542205506,"version":"3.54.5"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In vitro<\/jats:italic>\n                      dissolution is a critical quality control test in pharmaceutical development, used to measure the rate and extent at which an active pharmaceutical ingredient (API) is released from solid dosage forms, such as tablets, into solution under standardized conditions. It serves as a predictive tool for in vivo drug behavior, providing insights into drug release mechanisms and ensuring the development of robust, effective, and consistent products. Despite its importance, data on dissolution performance remain limited for certain drugs. As a rapid, reliable, and cost-effective method to estimate drug absorption, this study focused on evaluating the dissolution profiles of different brands of ciprofloxacin 500\u2009mg tablets and applying kinetic modeling to support regulatory decision-making.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty samples of ciprofloxacin 500\u2009mg tablets were collected from retail outlets in six selected sites of the West Gondar Zone including Humera, Mai Kadra, Metema, Gendawuha, Kokit, and Midregenet towns between January and July 2022. The samples were obtained from purposively selected outlets using prescription papers issued by the University of Gondar Comprehensive Hospital, following a mystery shopper approach in line with WHO (2015) strategies. All collected samples were transported to the Ethiopian Food and Drug Authority (EFDA) laboratory and conducted as per USP specification. The amount of ciprofloxacin released was quantified using UV-Vis spectrophotometry at 276\u2009nm. While the onset of pharmacological action was not directly measured, the Mean Dissolution Time (MDT) values suggested differences in release rates, which may influence the onset of action in vivo were considered. Dissolution profiles were evaluated using both model-independent parameters (difference factor f\u2081, similarity factor f\u2082, dissolution efficiency, and mean dissolution time) and model-dependent kinetics. Results were presented in tables, figures, and narrative form.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All of the included tablet brands complied with single-point dissolution study test, as their Active Pharmaceutical Ingredient release were greater than 80% within the specified 30 minutes time frame according to USP standards. Only 4 brands (21.05%) met the f1\/f2 similarity criteria. However, fifteen brands (78.95%) were not interchangeable with the comparator, as the difference factors (f1) were greater than 15% and the similarity factor (f2) were less than 50%. The mean dissolution time values ranged between 1.02 and 7.16 minutes, and the results showed that four of the twenty brands (4\/20) exhibited the fastest dissolution rate and onset of action. The evaluated brands followed the Korsmeyer-Peppas and Weibull curve approach (the highest coefficient of determination) for the release of drug substances from the dosage forms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study reveals that while all tested ciprofloxacin 500\u2009mg tablet brands complied with USP single-point dissolution criteria, only 21.05% met the similarity factor (f\u2082) and difference factor (f\u2081) standards for interchangeability with the comparator product. Significant variability in dissolution profiles among brands raises concerns regarding bioequivalence and potential implications for therapeutic efficacy and antimicrobial resistance. These findings underline the necessity for enhanced regulatory oversight, including routine dissolution profiling and, where appropriate, in vivo bioequivalence studies to ensure the quality and interchangeability of multisource ciprofloxacin products in Ethiopia and similar settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0350283","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:01:21Z","timestamp":1779998481000},"page":"e0350283","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vitro dissolution and release kinetics of multisource ciprofloxacin 500\u2009mg tablets in West Gondar, Ethiopia: Implications for interchangeability and regulatory oversight"],"prefix":"10.1371","volume":"21","author":[{"given":"Tewodros Denekew","family":"Haile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayenew","family":"Ashenef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chilot Abiyu","family":"Demeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeniewa Kerie","family":"Anagaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abibo Wondie","family":"Mekonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minichil Chanie","family":"Worku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asnakew Mulaw","family":"Beirhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesuneh Tefera","family":"Mekasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8780-2385","authenticated-orcid":true,"given":"Melaku Getahun","family":"Feleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"12","key":"pone.0350283.ref001","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","article-title":"Antibiotic resistance-the need for global solutions","volume":"13","author":"R Laxminarayan","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"pone.0350283.ref002","unstructured":"World Health Organization WHO. 19th World Health Organization model list of essential medicines. 2015. http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/EML2015_8May15.pdf"},{"issue":"2","key":"pone.0350283.ref003","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jac\/dkm109","article-title":"Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence","volume":"60","author":"T Kelesidis","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"pone.0350283.ref004","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002923","article-title":"Substandard and counterfeit medicines: a systematic review of the literature","volume":"3","author":"T Almuzaini","year":"2013","journal-title":"BMJ Open"},{"issue":"8","key":"pone.0350283.ref005","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1365-3156.2008.02106.x","article-title":"Substandard medicines in resource-poor settings: a problem that can no longer be ignored","volume":"13","author":"J-M Caudron","year":"2008","journal-title":"Trop Med Int Health"},{"issue":"12","key":"pone.0350283.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001139","article-title":"The primacy of public health considerations in defining poor quality medicines","volume":"8","author":"PN Newton","year":"2011","journal-title":"PLoS Med"},{"key":"pone.0350283.ref007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13756-017-0208-x","article-title":"The threat of antimicrobial resistance in developing countries: causes and control strategies","volume":"6","author":"JA Ayukekbong","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"issue":"3","key":"pone.0350283.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265271","article-title":"Prevalence and drug resistance patterns of Gram-negative enteric bacterial pathogens from diarrheic patients in Ethiopia: A systematic review and meta-analysis","volume":"17","author":"AM Beyene","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pone.0350283.ref009","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1186\/s12879-023-08803-x","article-title":"Antimicrobial resistance profiles of bacterial isolates from clinical specimens referred to Ethiopian Public Health Institute: analysis of 5-year data","volume":"23","author":"BT Regassa","year":"2023","journal-title":"BMC Infect Dis"},{"key":"pone.0350283.ref010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpharm.2008.12.026","article-title":"Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives","volume":"371","author":"SA Breda","year":"2009","journal-title":"Int J Pharm"},{"key":"pone.0350283.ref011","article-title":"Biopharmaceutics classification system-based biowaivers M9","author":"ICH","year":"2019","journal-title":"Int Counc Harmon Tech Requir Pharm Hum Use"},{"key":"pone.0350283.ref012","unstructured":"WHO. Pharmaceutical products: guidelines on registration requirements to establish interchangeability, Annex 7. 2006. World Health Organization. 2006."},{"issue":"6","key":"pone.0350283.ref013","first-page":"64","article-title":"Mathematical comparison of dissolution profiles","volume":"20","author":"J Moore","year":"1996","journal-title":"Pharmaceutical technology"},{"issue":"2","key":"pone.0350283.ref014","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"P Costa","year":"2001","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"pone.0350283.ref015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.2042-7158.1972.tb08930.x","article-title":"Linearization of dissolution rate curves by the Weibull distribution","volume":"24","author":"F Langenbucher","year":"1972","journal-title":"J Pharm Pharmacol"},{"key":"pone.0350283.ref016","unstructured":"Ethiopian Food and Drug Authority. Ethiopian Essential Medicines List. EFDA\/GDL\/067. 2024."},{"key":"pone.0350283.ref017","first-page":"117","article-title":"Assessment of Pharmaceutical Service Quality Provided in Community Drug Retail Outlets in Selected Towns, South West Ethiopia","volume":"11","author":"F Demissie","year":"2022","journal-title":"Integr Pharm Res Pract"},{"issue":"8","key":"pone.0350283.ref018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0308223","article-title":"Post-marketing quality surveillance of selected antibacterial agents marketed in porous borders; the case of Ethiopia-Sudan-Eritrea border","volume":"19","author":"T Denekew","year":"2024","journal-title":"PLoS One"},{"key":"pone.0350283.ref019","doi-asserted-by":"crossref","unstructured":"Endashaw E, Tatiparthi R, Mohammed T, Tefera Y, Teshome H, Duguma M. Dissolution profile evaluation of seven brands of amoxicillin-clavulanate potassium 625\u2009mg tablets retailed in Hawassa town, Sidama regional state, Ethiopia. 2023.","DOI":"10.21203\/rs.3.rs-2233110\/v2"},{"key":"pone.0350283.ref020","unstructured":"WHO. Antimicrobial resistance in the WHO African region: a systematic literature review. Brazzaville: World Health Organization. 2021."},{"key":"pone.0350283.ref021","first-page":"158","article-title":"Shortages of medicines: a complex global challenge","author":"A Gray","year":"2012","journal-title":"SciELO Public Health"},{"issue":"2","key":"pone.0350283.ref022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2471\/BLT.17.199562","article-title":"Medicines quality assurance to fight antimicrobial resistance","volume":"96","author":"J Nwokike","year":"2018","journal-title":"Bull World Health Organ"},{"key":"pone.0350283.ref023","unstructured":"WHO. World Health Organization Guidelines on the Conduct of Surveys of the Quality of Medicines. 2015."},{"key":"pone.0350283.ref024","unstructured":"WHO. World Health Organization Guidance on the Selection of Comparator Pharmaceutical Products for Equivalence Assessment of Interchangeable Multisource (Generic) Products. 2002."},{"key":"pone.0350283.ref025","volume-title":"USP monographs: Ciprofloxacin tablets","author":"Convention United States Pharmacopoeial","year":"2020"},{"issue":"1","key":"pone.0350283.ref026","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.2042-7158.1975.tb09378.x","article-title":"The concept of dissolution efficiency","volume":"27","author":"KA Khan","year":"1975","journal-title":"J Pharm Pharmacol"},{"key":"pone.0350283.ref027","unstructured":"FDA US. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. US Food and Drug Administration. 1997. https:\/\/www.fda.gov\/media\/70983\/download"},{"key":"pone.0350283.ref028","first-page":"1011","article-title":"Design and in-vitro evaluation of indapamide sustained release tablet using Methocel K15 Mcr and Methocel K100m Lvcr","volume":"3","author":"S Sanam","year":"2012","journal-title":"IJPSR"},{"issue":"10","key":"pone.0350283.ref029","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/pharmaceutics13101703","article-title":"A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products","volume":"13","author":"J Musel\u00edk","year":"2021","journal-title":"Pharmaceutics"},{"issue":"02","key":"pone.0350283.ref030","doi-asserted-by":"crossref","DOI":"10.4172\/2329-6631.1000171","article-title":"Application of Mathematical Models in Drug Release Kinetics of Carbidopa and Levodopa ER Tablets","volume":"06","author":"H Baishya","year":"2017","journal-title":"J Dev Drugs"},{"issue":"3","key":"pone.0350283.ref031","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","article-title":"DDSolver: an add-in program for modeling and comparison of drug dissolution profiles","volume":"12","author":"Y Zhang","year":"2010","journal-title":"AAPS J"},{"key":"pone.0350283.ref032","unstructured":"European Medicines Agency EMA. Note for guidance on the investigation of bioavailability and bioequivalence. 2010. http:\/\/tinyurl.com\/36d2q68S"},{"key":"pone.0350283.ref033","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/B978-0-444-53242-8.00012-6","article-title":"Oral Drug Absorption, Evaluation, and Prediction","author":"Y Yang","year":"2009","journal-title":"Developing Solid Oral Dosage Forms. Elsevier"},{"issue":"2","key":"pone.0350283.ref034","doi-asserted-by":"crossref","DOI":"10.38212\/2224-6614.2298","article-title":"In vitro testing of ciprofloxacin formulations and preliminary study on BCS biowaiver","volume":"17","author":"SB Kyriacos","year":"2020","journal-title":"Journal of Food and Drug Analysis"},{"issue":"4","key":"pone.0350283.ref035","first-page":"298","article-title":"Post-market in vitro bioequivalence study of six brands of ciprofloxacin tablets\/caplets in Jos, Nigeria","volume":"4","author":"N Ngwuluka","year":"2009","journal-title":"Scientific Research and Essays"},{"issue":"6","key":"pone.0350283.ref036","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17180","article-title":"Post-market quality assessment of 22 ciprofloxacin brands by HPLC available in Bangladesh market","volume":"9","author":"MH Shohag","year":"2023","journal-title":"Heliyon"},{"issue":"4","key":"pone.0350283.ref037","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1081\/DDC-120003003","article-title":"Bioequivalence of two brands of ciprofloxacin 750\u2009mg tablets (Sarf and Ciprobay) in healthy human volunteers","volume":"28","author":"RM Abdallah","year":"2002","journal-title":"Drug Dev Ind Pharm"},{"key":"pone.0350283.ref038","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902023e22725","article-title":"Interchangeability of medications and biopharmaceutical implication of taking drugs with fluids other than water: ibuprofen case study","volume":"59","author":"NB Paji\u0107","year":"2023","journal-title":"Braz J Pharm Sci"},{"issue":"5","key":"pone.0350283.ref039","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1345\/aph.1K560","article-title":"Comparison of simvastatin tablets from the US and international markets obtained via the Internet","volume":"42","author":"MA Veronin","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"4","key":"pone.0350283.ref040","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jpba.2004.11.041","article-title":"Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles","volume":"37","author":"P Bertocchi","year":"2005","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"pone.0350283.ref041","doi-asserted-by":"crossref","DOI":"10.3126\/kuset.v3i1.64175","article-title":"Comparative In Vitro Evaluation of Commercially Available Pantoprazole Tablets","volume":"3","author":"S Mansoor","year":"2007","journal-title":"Kathmandu University J of Sci, Engineering & Technol"},{"key":"pone.0350283.ref042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rinphs.2011.12.001","article-title":"The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing","volume":"2","author":"MN Al Ameri","year":"2011","journal-title":"Results Pharma Sci"},{"issue":"2","key":"pone.0350283.ref043","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-003-0587-1","article-title":"Drug formulations intended for the global market should be tested for stability under tropical climatic conditions","volume":"59","author":"PG Risha","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"pone.0350283.ref044","doi-asserted-by":"crossref","DOI":"10.26719\/2007.13.6.1427","article-title":"Assessment of the pharmaceutical quality of omeprazole capsule brands marketed in Egypt","volume":"13","author":"A El-Sayed","year":"2007","journal-title":"Eastern Mediterranean health journal"},{"issue":"6","key":"pone.0350283.ref045","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11096-010-9429-2","article-title":"Generic and therapeutic substitutions: are they always ethical in their own terms?","volume":"32","author":"M AlAmeri","year":"2010","journal-title":"Pharmacy world & science"},{"issue":"5","key":"pone.0350283.ref046","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0009-9236(03)00010-9","article-title":"\u201cInactive\u201d excipients such as Cremophor can affect in vivo drug disposition","volume":"73","author":"C Wandel","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"pone.0350283.ref047","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/dtb.2009.06.0026","article-title":"What are excipients doing in medicinal products?","volume":"47","year":"2009","journal-title":"Drug Ther Bull"},{"issue":"4","key":"pone.0350283.ref048","first-page":"371","article-title":"Determination of simvastatin in pharmaceutical dosage forms by optimized and validated method using HPLC\/UV","volume":"83","author":"L Guzik","year":"2010","journal-title":"Croatica chemica Acta"},{"key":"pone.0350283.ref049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.07.011","article-title":"A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system","volume":"321","author":"A Dokoumetzidis","year":"2006","journal-title":"Int J Pharm"},{"issue":"3","key":"pone.0350283.ref050","first-page":"220","article-title":"Comparative quality assessment of acetaminophen immediate and extended release tablets by validated analytical methods","volume":"1","author":"A Islam","year":"2012","journal-title":"IJPRBS"},{"issue":"2","key":"pone.0350283.ref051","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4103\/0250-474X.91579","article-title":"Formulation and evaluation of a sustained-release tablets of metformin hydrochloride using hydrophilic synthetic and hydrophobic natural polymers","volume":"73","author":"KJ Wadher","year":"2011","journal-title":"Indian J Pharm Sci"},{"issue":"2","key":"pone.0350283.ref052","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3329\/dujps.v10i2.11785","article-title":"Development and in vitro Evaluation of Sustained Release Matrix Tablets of Indapamide from Methocel\u00ae K15 MCR and K100 LVCR","volume":"10","author":"U Das","year":"2012","journal-title":"Dhaka Univ J Pharm Sci"},{"issue":"5","key":"pone.0350283.ref053","first-page":"085","article-title":"Development and evaluation of sustained release matrix tablets of indapamide using Methocel K15M CR","volume":"3","author":"MA Hossain","year":"2013","journal-title":"Journal of Applied Pharmaceutical Science"},{"key":"pone.0350283.ref054","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jps.2600501018","article-title":"Rate of release of medicaments from ointment bases containing drugs in suspension","volume":"50","author":"T HIGUCHI","year":"1961","journal-title":"J Pharm Sci"},{"key":"pone.0350283.ref055","article-title":"In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs","author":"JB Dressman","year":"2000","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"pone.0350283.ref056","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.eswa.2006.02.019","article-title":"Unified methodology of neural analysis in decision support systems built for pharmaceutical technology","volume":"32","author":"A Mendyk","year":"2007","journal-title":"Expert Systems with Applications"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0352706","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000}}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:01:32Z","timestamp":1779998492000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350283"}},"subtitle":[],"editor":[{"given":"Peter Mbugua","family":"Njogu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0350283","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}